title: Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
authors.forename: Mogens K
authors.initials: MK
authors.lastname: Boisen
authors.forename: Julia S
authors.initials: JS
authors.lastname: Johansen
authors.forename: Ole
authors.initials: O
authors.lastname: Larsen
authors.forename: Benny V
authors.initials: BV
authors.lastname: Jensen
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D012107:Research Design
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin